Impact of Antidepressant Black Box Juggled By Advisory Committee, FDA

The addition of new, positive data on adult suicidality to antidepressant labeling could be an opportunity to offset the negative impact the "black box" warning on pediatric suicidality has had on antidepressant use, according to members of FDA's Psychopharmacologic Drugs Advisory Committee